Market by Therapeutic Application, Technology, Treatment Type, Product, Application, and Country | Forecast 2021-2028
The Asia-Pacific market for
stem cell is likely to exhibit growth at 8.14% of CAGR during the evaluated
years 2021-2028.
Report scope can be customized per your requirements. Request For Customization
The countries reviewed in this
market include:
• India
• China
• Japan
• Australia & New Zealand
• South Korea
• ASEAN countries
• Rest of APAC
In China, the stem cell market
is growing rapidly, owing to the government’s increasing efforts in
strengthening the biotech industry. For instance, in 2019, the government
granted 18 billion to biotechnology research under its five-year plan.
Moreover, the regulatory framework for stem cell research, continual
modernization of the healthcare sector, and rising public and private
initiatives to influence the use of stem cell treatments, are also motivating
the development of the studied market.
Furthermore, advancement in
the concentration on clinical research, technological developments,
regenerative medicines, and rising chronic diseases are another set of factors
fueling the expansion of the stem cell market across China.
In India, the stem cell market
is driven primarily due to multiple factors, including the high demand for
regenerative treatment alternatives. The surge in the awareness about the
importance of stem cell therapies in treating terminal conditions is also
majorly influencing the studied market’s expansion. Additionally, numerous
companies associated with stem cells are extending their business operations in
the region. For instance, the Global Institute of Stem Cell Therapy and
Research inaugurated a stem cell/ cancer research therapy center in Chandigarh.
Hence, the increasing privatization, along with awareness about stem cell
therapies are likely to augment the stem cell market in India.
Takara Holdings is a
biotechnology company conducting business through different segments, such as
gene therapy, Agri-bio, and bio industry. It provides its clientele with health
foods, gene and cell therapies, raw alcohol, and seasonings, among others, via
its subsidiaries. Moreover, its products are widely used for application in
regenerative medicine research, along with the estimated candidate substance of
the drugs. The company has its operations spread across various regions, with
its headquarter set in Japan.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC
STEM CELL MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. PORTER’S
FIVE FORCES MODEL
2.1.1. THREAT
OF NEW ENTRANTS
2.1.2. THREAT
OF SUBSTITUTE PRODUCTS
2.1.3. BARGAINING
POWER OF BUYERS
2.1.4. BARGAINING
POWER OF SUPPLIERS
2.1.5. COMPETITIVE
RIVALRY
2.2. IMPACT
OF COVID-19 ON STEM CELL MARKET
2.3. KEY
IMPACT ANALYSIS
2.4. INDUSTRY
COMPONENTS
2.5. LEGAL,
POLICY, & REGULATORY FRAMEWORK
2.6. MARKET
ATTRACTIVENESS INDEX
2.7. VENDOR
SCORECARD
2.8. KEY
INSIGHTS
2.9. MARKET
DRIVERS
2.9.1. GROWING
AWARENESS ABOUT UMBILICAL CORD STEM CELLS
2.9.2. SURGE
IN STEM CELL RESEARCH AND DEVELOPMENT
2.9.3. RISING
DEMAND FOR REGENERATIVE MEDICINE
2.10. MARKET RESTRAINTS
2.10.1. ETHICAL CONCERNS ASSOCIATED
WITH STEM CELLS
2.10.2. HIGH COST OF STEM CELL
PROCEDURES
2.10.3. STRINGENT REGULATIONS IN TERMS
OF STEM CELL THERAPY
2.11. MARKET OPPORTUNITIES
2.11.1. ADVANCEMENT IN TECHNOLOGY
2.11.2. RISK OF ADVERSE IMMUNE
REACTIONS AND COMPLICATIONS
3. ASIA-PACIFIC
STEM CELL MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
3.1. NEUROLOGICAL
DISORDERS
3.2. ONCOLOGY
DISORDERS
3.3. DIABETES
3.4. INJURIES
AND WOUNDS
3.5. ORTHOPEDIC
TREATMENTS
3.6. CARDIOVASCULAR
DISORDERS
3.7. OTHER
THERAPEUTIC APPLICATIONS
4. ASIA-PACIFIC
STEM CELL MARKET OUTLOOK - BY TECHNOLOGY
4.1. CRYOPRESERVATION
4.2. ACQUISITION
4.2.1. STEM
CELL APHERESIS
4.2.2. STEM
CELL BONE MARROW MARKET
4.2.3. STEM
CELL UMBILICAL CORD
4.3. EXPANSION
AND SUB-CULTURE
4.4. PRODUCTION
4.4.1. STEM
CELL CULTURE
4.4.2. THERAPEUTIC
CLONING
4.4.3. IVF
5. ASIA-PACIFIC
STEM CELL MARKET OUTLOOK - BY TREATMENT TYPE
5.1. ALLOGENEIC
STEM CELL THERAPY
5.2. AUTOLOGIC
STEM CELL THERAPY
5.3. SYNGENEIC
STEM CELL THERAPY
6. ASIA-PACIFIC
STEM CELL MARKET OUTLOOK - BY PRODUCT
6.1. ADULT
STEM CELL
6.1.1. HEMATOPOIETIC
STEM CELL
6.1.2. NEURAL
STEM CELL
6.1.3. UMBILICAL
CORD STEM CELL
6.1.4. MESENCHYMAL
STEM CELL
6.1.5. DENTAL
STEM CELL
6.2. HUMAN
EMBRYONIC STEM CELL
6.3. PLURIPOTENT
6.4. MOUSE/RAT
NEURAL
7. ASIA-PACIFIC
STEM CELL MARKET OUTLOOK - BY APPLICATION
7.1. REGENERATIVE
MEDICINE
7.2. DRUG
DISCOVERY AND DEVELOPMENT
8. GEOGRAPHICAL
ANALYSIS - ASIA PACIFIC
8.1. COUNTRY
ANALYSIS
8.1.1. CHINA
8.1.2. JAPAN
8.1.3. INDIA
8.1.4. AUSTRALIA
& NEW ZEALAND
8.1.5. SOUTH
KOREA
8.1.6. ASEAN
COUNTRIES
8.1.7. REST
OF ASIA-PACIFIC
9. COMPANY
PROFILES
9.1. CORNING
INC
9.2. STEMCELL
TECHNOLOGIES
9.3. STRYKER
CORPORATION
9.4. BECTON
DICKINSON AND COMPANY (BD)
9.5. CYTORI
THERAPEUTICS
9.6. QIAGEN
NV
9.7. GE
HEALTHCARE
9.8. TAKARA
HOLDINGS
9.9. SMITH
& NEPHEW PLC
9.10. INTERNATIONAL STEM CELL CORP
9.11. MILTENYI BIOTEC
9.12. MERCK KGAA (SIGMA ALDRICH)
9.13. THERMO FISHER SCIENTIFIC INC
9.14. ALLCELLS LLC
9.15. PLURISTEM THERAPEUTICS INC
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH SCOPE &
DELIVERABLES
10.1.1. OBJECTIVES OF STUDY
10.1.2. SCOPE OF STUDY
10.2. SOURCES OF DATA
10.2.1. PRIMARY DATA SOURCES
10.2.2. SECONDARY DATA SOURCES
10.3. RESEARCH METHODOLOGY
10.3.1. EVALUATION OF PROPOSED MARKET
10.3.2. IDENTIFICATION OF DATA SOURCES
10.3.3. ASSESSMENT OF MARKET
DETERMINANTS
10.3.4. DATA COLLECTION
10.3.5. DATA VALIDATION & ANALYSIS
TABLE 1 ASIA-PACIFIC STEM CELL MARKET, BY COUNTRY, 2021-2028 (IN $
MILLION)
TABLE 2 VENDOR SCORECARD
TABLE 3 ASIA-PACIFIC STEM CELL MARKET, BY THERAPEUTIC APPLICATION,
2021-2028 (IN $ MILLION)
TABLE 4 ASIA-PACIFIC STEM CELL MARKET, BY TECHNOLOGY, 2021-2028 (IN $
MILLION)
TABLE 5 ASIA-PACIFIC ACQUISITION MARKET, BY TYPE, 2021-2028 (IN $
MILLION)
TABLE 6 ASIA-PACIFIC PRODUCTION MARKET, BY TYPE, 2021-2028 (IN $
MILLION)
TABLE 7 ASIA-PACIFIC STEM CELL MARKET, BY TREATMENT TYPE, 2021-2028
(IN $ MILLION)
TABLE 8 ASIA-PACIFIC STEM CELL MARKET, BY PRODUCT, 2021-2028 (IN $
MILLION)
TABLE 9 ASIA-PACIFIC ADULT STEM CELL MARKET, BY TYPE, 2021-2028 (IN $
MILLION)
TABLE 10 ASIA-PACIFIC STEM CELL MARKET, BY
APPLICATION, 2021-2028 (IN $ MILLION)
TABLE 11 ASIA-PACIFIC STEM CELL MARKET, BY COUNTRY,
2021-2028 (IN $ MILLION)
FIGURE 1 ASIA-PACIFIC STEM CELL MARKET 2021-2028
(IN $ MILLION)
FIGURE 2 ASIA-PACIFIC STEM CELL MARKET, BY
NEUROLOGICAL DISORDERS, 2021-2028 (IN $ MILLION)
FIGURE 3 ASIA-PACIFIC STEM CELL MARKET, BY ONCOLOGY
DISORDERS, 2021-2028 (IN $ MILLION)
FIGURE 4 ASIA-PACIFIC STEM CELL MARKET, BY
DIABETES, 2021-2028 (IN $ MILLION)
FIGURE 5 ASIA-PACIFIC STEM CELL MARKET, BY INJURIES
AND WOUNDS, 2021-2028 (IN $ MILLION)
FIGURE 6 ASIA-PACIFIC STEM CELL MARKET, BY
ORTHOPEDIC TREATMENTS, 2021-2028 (IN $ MILLION)
FIGURE 7 ASIA-PACIFIC STEM CELL MARKET, BY
CARDIOVASCULAR DISORDERS, 2021-2028 (IN $ MILLION)
FIGURE 8 ASIA-PACIFIC STEM CELL MARKET, BY OTHER
THERAPEUTIC APPLICATIONS, 2021-2028 (IN $ MILLION)
FIGURE 9 ASIA-PACIFIC STEM CELL MARKET, BY
CRYOPRESERVATION, 2021-2028 (IN $ MILLION)
FIGURE 10 ASIA-PACIFIC STEM CELL MARKET, BY
ACQUISITION, 2021-2028 (IN $ MILLION)
FIGURE 11 ASIA-PACIFIC STEM CELL MARKET, BY STEM CELL
APHERESIS, 2021-2028 (IN $ MILLION)
FIGURE 12 ASIA-PACIFIC STEM CELL MARKET, BY STEM CELL
BONE MARROW MARKET, 2021-2028 (IN $ MILLION)
FIGURE 13 ASIA-PACIFIC STEM CELL MARKET, BY STEM CELL
UMBILICAL CORD, 2021-2028 (IN $ MILLION)
FIGURE 14 ASIA-PACIFIC STEM CELL MARKET, BY EXPANSION
AND SUB-CULTURE, 2021-2028 (IN $ MILLION)
FIGURE 15 ASIA-PACIFIC STEM CELL MARKET, BY PRODUCTION,
2021-2028 (IN $ MILLION)
FIGURE 16 ASIA-PACIFIC STEM CELL MARKET, BY STEM CELL
CULTURE, 2021-2028 (IN $ MILLION)
FIGURE 17 ASIA-PACIFIC STEM CELL MARKET, BY THERAPEUTIC
CLONING, 2021-2028 (IN $ MILLION)
FIGURE 18 ASIA-PACIFIC STEM CELL MARKET, BY IVF,
2021-2028 (IN $ MILLION)
FIGURE 19 ASIA-PACIFIC STEM CELL MARKET, BY ALLOGENEIC
STEM CELL THERAPY, 2021-2028 (IN $ MILLION)
FIGURE 20 ASIA-PACIFIC STEM CELL MARKET, BY AUTOLOGIC
STEM CELL THERAPY, 2021-2028 (IN $ MILLION)
FIGURE 21 ASIA-PACIFIC STEM CELL MARKET, BY SYNGENEIC
STEM CELL THERAPY, 2021-2028 (IN $ MILLION)
FIGURE 22 ASIA-PACIFIC STEM CELL MARKET, BY ADULT STEM
CELL, 2021-2028 (IN $ MILLION)
FIGURE 23 ASIA-PACIFIC STEM CELL MARKET, BY
HEMATOPOIETIC STEM CELL, 2021-2028 (IN $ MILLION)
FIGURE 24 ASIA-PACIFIC STEM CELL MARKET, BY NEURAL STEM
CELL, 2021-2028 (IN $ MILLION)
FIGURE 25 ASIA-PACIFIC STEM CELL MARKET, BY UMBILICAL
CORD STEM CELL, 2021-2028 (IN $ MILLION)
FIGURE 26 ASIA-PACIFIC STEM CELL MARKET, BY MESENCHYMAL
STEM CELL, 2021-2028 (IN $ MILLION)
FIGURE 27 ASIA-PACIFIC STEM CELL MARKET, BY DENTAL STEM
CELL, 2021-2028 (IN $ MILLION)
FIGURE 28 ASIA-PACIFIC STEM CELL MARKET, BY HUMAN
EMBRYONIC STEM CELL, 2021-2028 (IN $ MILLION)
FIGURE 29 ASIA-PACIFIC STEM CELL MARKET, BY
PLURIPOTENT, 2021-2028 (IN $ MILLION)
FIGURE 30 ASIA-PACIFIC STEM CELL MARKET, BY MOUSE/RAT
NEURAL, 2021-2028 (IN $ MILLION)
FIGURE 31 ASIA-PACIFIC STEM CELL MARKET, BY
REGENERATIVE MEDICINE, 2021-2028 (IN $ MILLION)
FIGURE 32 ASIA-PACIFIC STEM CELL MARKET, BY DRUG
DISCOVERY AND DEVELOPMENT, 2021-2028 (IN $ MILLION)
FIGURE 33 CHINA STEM CELL MARKET 2021-2028 (IN $
MILLION)
FIGURE 34 JAPAN STEM CELL MARKET 2021-2028 (IN $
MILLION)
FIGURE 35 INDIA STEM CELL MARKET 2021-2028 (IN $
MILLION)
FIGURE 36 AUSTRALIA & NEW ZEALAND STEM CELL MARKET
2021-2028 (IN $ MILLION)
FIGURE 37 SOUTH KOREA SURGICAL STEM CELL MARKET
2021-2028 (IN $ MILLION)
FIGURE 38 ASEAN COUNTRIES STEM CELL MARKET 2021-2028
(IN $ MILLION)
FIGURE 39 REST OF ASIA-PACIFIC STEM CELL MARKET
2021-2028 (IN $ MILLION)